Regeneron Announces Approval of Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous-Cell Carcinoma with a High Risk of Recurrence After Surgery and Radiation
October 8, 2025
The first and only FDA-approved immunotherapy for this patient population October 8, 2025 (Sacramento, California) The FDA has approved the…